Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer

NCT06092242 is registered in ClinicalTrials.gov with The Second Affiliated Hospital of Shandong First Medical University as lead sponsor.

NCT NCT06092242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06092242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer
Lead sponsor
The Second Affiliated Hospital of Shandong First Medical University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 15, 2023
Completion date
October 15, 2027
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer